165 lbs lost on GLP-1s: What the science says about extreme weight loss claims

What's this video probably claiming?

Based on the caption "165 lbs gone and counting. NO REGRETS," this creator is almost certainly sharing a dramatic personal weight loss journey attributed to GLP-1 receptor agonists, most likely semaglutide (Wegovy/Ozempic) or tirzepatide (Zepbound/Mounjaro). Videos in this category typically combine before-and-after visuals with enthusiastic endorsements of the medication, often framing the drug as a near-effortless solution. The "NO REGRETS" phrasing signals the creator is also probably addressing side effects or critics who've questioned their choice to use GLP-1 therapy. At 70.7K views, this video is reaching a meaningful audience, many of whom may be early in their decision-making process about these medications. Expect claims about sustained appetite suppression, rapid body composition changes, and possibly dismissals of common side effects like nausea, vomiting, or muscle loss. Whether intentional or not, videos like this tend to imply that results of this magnitude are typical, achievable quickly, and without significant trade-offs.

What does the science actually show?

Let's be precise here. The STEP 1 trial (Wilding et al., 2021, NEJM) found that semaglutide 2.4 mg weekly produced an average weight loss of 14.9% of body weight over 68 weeks in adults with obesity and no diabetes. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at its highest dose (15 mg) produced average weight loss of 20.9% over 72 weeks. Those are averages. The top responders in these trials, roughly the top quartile, did lose significantly more, but 165 lbs represents an extraordinary outcome that sits well outside the median clinical result. It is not fabricated territory, particularly for someone with a very high starting body weight, but it is not what most patients should expect. Critically, both trials required concurrent lifestyle intervention. The drug alone did not produce these numbers in isolation. Muscle loss is also a real concern: a 2024 analysis published in Diabetes, Obesity and Metabolism noted that a meaningful proportion of GLP-1-driven weight loss includes lean mass reduction, not just fat.

Where does the social media noise diverge from clinical reality?

The biggest gap between TikTok GLP-1 content and clinical reality is survivorship bias. You are watching the person who lost 165 lbs. You are not watching the person who lost 18 lbs, plateaued, and stopped the medication due to cost or side effects. The STEP 1 trial reported that 84% of participants experienced gastrointestinal side effects, with nausea affecting roughly half. That is not a minor footnote. The "NO REGRETS" framing actively discourages potential patients from taking side effect profiles seriously before starting. There is also the rebound problem. A 2022 study by Wilding et al. in Diabetes, Obesity and Metabolism found that patients regained approximately two-thirds of lost weight within one year of discontinuing semaglutide. GLP-1 therapy appears to require indefinite use to maintain results for most patients, a financial and logistical reality that social media transformations almost never address. Cost, insurance access, and compounded drug quality variation are entirely absent from the viral weight loss narrative.

What should you actually know?

GLP-1 receptor agonists are among the most effective pharmacological tools for obesity medicine developed in decades. That is not hype, that is what randomized controlled trial data shows. But "effective" and "simple" are not the same thing. A loss of 165 lbs, if accurate, likely reflects a combination of GLP-1 therapy, significant dietary changes, possibly surgical history the creator has not disclosed, a high baseline body weight, and a favorable individual response to the medication. Before starting any GLP-1 therapy, patients should discuss cardiovascular history, as semaglutide received FDA indication for cardiovascular risk reduction in high-risk patients per the SELECT trial (Lincoff et al., 2023, NEJM), thyroid cancer history given the black box warning on this drug class, and a realistic timeline and goal. Viral success stories are not a treatment plan. A supervised program with a licensed provider, regular metabolic monitoring, and honest discussion of discontinuation risks is what the evidence actually supports.